{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:38:28Z","timestamp":1771457908355,"version":"3.50.1"},"reference-count":50,"publisher":"BMJ","issue":"22","funder":[{"name":"MFO was awarded with a EACVI training grant (Cardio-Oncology and CV Imaging) in 2020"},{"name":"CM is supported directly and indirectly by University College London Hospitals National Institute of Health Research Biomedical Research Centre"},{"name":"AH is supported by the Clinical Research Training Fellowship, British Heart Foundation","award":["FS\/20\/13\/34857"],"award-info":[{"award-number":["FS\/20\/13\/34857"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2021,2,17]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>Multiple myeloma (MM) is the third most common haematological malignancy, with increasing prevalence over recent years. Advances in therapy have improved survival, changing the clinical course of MM into a chronic condition and meaning that management of comorbidities is fundamental to improve clinical outcomes. Cardiovascular (CV) events affect up to 7.5% of individuals with MM, due to a combination of patient, disease and treatment-related factors and adversely impact survival. MM typically affects older people, many with pre-existing CV risk factors or established CV disease, and the disease itself can cause renal impairment, anaemia and hyperviscosity, which exacerabate these further. Up to 15% of patients with MM develop systemic amyloidosis, with prognosis determined by the extent of cardiac involvement. Management of MM generally involves administration of multiple treatment lines over several years as disease progresses, with many drug classes associated with adverse CV effects including high rates of venous and arterial thrombosis alongside heart failure. Recommendations for holistic management of patients with MM now include routine baseline risk stratification including ECG and echocardiography and administration of thromboprophylaxis drugs for patients treated with immunomodulatory drugs. Close surveillance of high-risk patients with collaboration between haematology and cardiology is required, with prompt investigation in the event of CV symptoms, in order to identify and treat complications early. Decisions regarding discontinuation of cardiotoxic therapies should be made in a multidisciplinary setting, taking into account the severity of the complication, prognosis, expected benefits and the availability of effective alternatives.<\/jats:p>","DOI":"10.1136\/heartjnl-2020-318748","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T13:20:14Z","timestamp":1617628814000},"page":"1774-1782","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Optimising cardiovascular care of patients with multiple myeloma"],"prefix":"10.1136","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6691-9146","authenticated-orcid":false,"given":"Marta","family":"Fontes Oliveira","sequence":"first","affiliation":[{"name":"Department of Cardio-Oncology, St Bartholomew's Hospital, London, UK"},{"name":"Department of Cardiology, Centro Hospitalar Universit\u00e1rio do Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-7042","authenticated-orcid":false,"given":"Willeke R","family":"Naaktgeboren","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2648-7326","authenticated-orcid":false,"given":"Alina","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4992-2412","authenticated-orcid":false,"given":"Arjun K","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Cardio-Oncology, St Bartholomew's Hospital, London, UK"},{"name":"Hatter Institute, London, UK"}]},{"given":"Heather","family":"Oakervee","sequence":"additional","affiliation":[{"name":"Department of Haemato-Oncology, St Bartholomew's Hospital, London, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-4782","authenticated-orcid":false,"given":"Simon","family":"Hallam","sequence":"additional","affiliation":[{"name":"Department of Haemato-Oncology, St Bartholomew's Hospital, London, UK"},{"name":"Queen Mary University of London, London, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-7090","authenticated-orcid":false,"given":"Charlotte","family":"Manisty","sequence":"additional","affiliation":[{"name":"Department of Cardio-Oncology, St Bartholomew's Hospital, London, UK"},{"name":"University College London, London, UK"}]}],"member":"239","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"2025092006405409000_107.22.1774.1","unstructured":"American Cancer Society . Cancer Facts & Statistics. Available: http:\/\/cancerstatisticscenter.cancer.org\/ [Accessed 27 Sep 2020]."},{"key":"2025092006405409000_107.22.1774.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"2025092006405409000_107.22.1774.3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025092006405409000_107.22.1774.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1857-x","article-title":"The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study","volume":"15","author":"Mohammadi","year":"2015","journal-title":"BMC Cancer"},{"key":"2025092006405409000_107.22.1774.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1"},{"key":"2025092006405409000_107.22.1774.6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2916.2916","article-title":"Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice","volume":"120","author":"Kistler","year":"2012","journal-title":"Blood"},{"key":"2025092006405409000_107.22.1774.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2955-0"},{"key":"2025092006405409000_107.22.1774.8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-137309","article-title":"Clinical features and survival outcomes in diabetic patients with newly diagnosed multiple myeloma (NDMM) enrolled in the Connect\u00ae MM registry","volume":"136","author":"La","year":"2020","journal-title":"Blood"},{"key":"2025092006405409000_107.22.1774.9","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.307"},{"key":"2025092006405409000_107.22.1774.10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/btpr.2441","article-title":"A novel cholesterol\/lipid delivery system for murine myeloma cell lines","volume":"33","author":"Chauhan","year":"2017","journal-title":"Biotechnol Prog"},{"key":"2025092006405409000_107.22.1774.11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000442511","article-title":"Current trends of renal impairment in multiple myeloma","volume":"1","author":"Yadav","year":"2016","journal-title":"Kidney Dis"},{"key":"2025092006405409000_107.22.1774.12","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"2025092006405409000_107.22.1774.13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.humpath.2018.09.008","article-title":"IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases","volume":"84","author":"Angelova","year":"2019","journal-title":"Hum Pathol"},{"key":"2025092006405409000_107.22.1774.14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199709059685","article-title":"Incidence and impact of light chain associated (al) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation","volume":"27","author":"Desikan","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"2025092006405409000_107.22.1774.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2271"},{"key":"2025092006405409000_107.22.1774.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.053"},{"key":"2025092006405409000_107.22.1774.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu506"},{"key":"2025092006405409000_107.22.1774.18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"2025092006405409000_107.22.1774.19","first-page":"455","article-title":"Prognostic significance of Holter monitor findings in patients with light chain amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2025092006405409000_107.22.1774.20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/anec.12018","article-title":"The findings of electrocardiography in patients with cardiac amyloidosis","volume":"18","author":"Cheng","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"2025092006405409000_107.22.1774.21","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302353"},{"key":"2025092006405409000_107.22.1774.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"2025092006405409000_107.22.1774.23","unstructured":"Home - electronic medicines compendium (emc). Available: https:\/\/www.medicines.org.uk\/emc#gref [Accessed 24 Oct 2020]."},{"key":"2025092006405409000_107.22.1774.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087671"},{"key":"2025092006405409000_107.22.1774.25","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025092006405409000_107.22.1774.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"2025092006405409000_107.22.1774.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.03.007"},{"key":"2025092006405409000_107.22.1774.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.139"},{"key":"2025092006405409000_107.22.1774.29","doi-asserted-by":"publisher","DOI":"10.4065\/80.12.1568"},{"key":"2025092006405409000_107.22.1774.30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.293"},{"key":"2025092006405409000_107.22.1774.31","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1981.00340060066015"},{"key":"2025092006405409000_107.22.1774.32","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20904"},{"key":"2025092006405409000_107.22.1774.33","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.58"},{"key":"2025092006405409000_107.22.1774.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"2025092006405409000_107.22.1774.35","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-312103"},{"key":"2025092006405409000_107.22.1774.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-705210"},{"key":"2025092006405409000_107.22.1774.37","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14787"},{"key":"2025092006405409000_107.22.1774.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"2025092006405409000_107.22.1774.39","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007724"},{"key":"2025092006405409000_107.22.1774.40","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-1-201107050-00004"},{"key":"2025092006405409000_107.22.1774.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01815.x"},{"key":"2025092006405409000_107.22.1774.42","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines","volume":"21 Suppl 5","author":"Bovelli","year":"2010","journal-title":"Ann Oncol"},{"key":"2025092006405409000_107.22.1774.43","unstructured":"Lyon AR , Dent S , Stanway S , et al . Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study group of the heart failure association of the European Society of cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure 2020."},{"key":"2025092006405409000_107.22.1774.44","unstructured":"\u010celutkien\u0117 J , Pudil R , L\u00f3pez-Fern\u00e1ndez T . Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the heart failure association (HFA), the European association of cardiovascular imaging (EACVI) and the Cardio-Oncology Council of the European Society of cardiology (ESC). Eur J Heart Fail 2020."},{"key":"2025092006405409000_107.22.1774.45","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ajh.25778","article-title":"Statin use is associated with improved survival in multiple myeloma: a Swedish population-based study of 4315 patients","volume":"95","author":"Br\u00e5nvall","year":"2020","journal-title":"Am J Hematol"},{"key":"2025092006405409000_107.22.1774.46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"JCO"},{"key":"2025092006405409000_107.22.1774.47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"2025092006405409000_107.22.1774.48","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"key":"2025092006405409000_107.22.1774.49","doi-asserted-by":"publisher","DOI":"10.1111\/jce.12123"},{"key":"2025092006405409000_107.22.1774.50","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (al) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2020-318748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T13:41:07Z","timestamp":1758375667000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2020-318748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":50,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,10,27]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/heartjnl-2020-318748"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2020-318748","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]}}}